CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

  • STATUS
    Recruiting
  • End date
    Sep 1, 2023
  • participants needed
    25
  • sponsor
    Catapult Therapeutics
Updated on 1 October 2021
platelet count
fludarabine
cyclophosphamide
chronic lymphocytic leukemia
rituximab
TP53
ibrutinib
bendamustine
acalabrutinib

Summary

Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged <65 years without del17p/TP53 mutations or bendamustine and rituximab for patients 65 years who have additional comorbidities).

Despite the gradual introduction of targeted therapies, new treatment strategies efficacious for patients ineligible for/unresponsive to these therapies are still required. These new strategies should ideally overcome disease relapse and circumvent compound-specific safety challenges. Emerging treatment options include new compounds aimed for both untreated and relapsed/refractory CLL, and combination therapies of existing compounds that extend single-agent efficacy in specific high-risk patient populations.

CAP-100 is expected to prevent the migration of leukemia cells to and their survival in lymphoid niches as well as to eliminate CCR7-positive leukemia cells via ADCC, resulting in measurable clinical responses.

The present trial is the first-in-human trial of CAP-100 and is divided into two phases. The aim of the Phase Ia (dose escalation) is to define the Recommended Phase 2 Dose (RP2D) versus the Maximum Tolerated Dose (MTD) of CAP-100 in subjects with CLL.

Phase Ib of the trial (expansion phase) will evaluate the safety and preliminary clinical benefit of CAP-100 monotherapy at RP2D (response rate, lymph node size reduction, assessment of minimal residual disease [MRD]) to support the design of future trials investigating CAP-100 either as monotherapy or in a combination setting with approved treatments for CLL.

Details
Condition SLL, Chronic Lymphocytic Leukemia, leukemia chronic lymphocytic, Lymphocytic Leukemia, Chronic, b-cell small lymphocytic lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia (cll)
Treatment CAP-100
Clinical Study IdentifierNCT04704323
SponsorCatapult Therapeutics
Last Modified on1 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years
Able to understand and sign a written informed consent document
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Relapsed or refractory to at least two (2) prior standard systemic treatment regimen for CLL or SLL and without available therapies known to provide clinical benefit
Prior CLL or SLL systemic therapy must have been discontinued for a duration of at least five times its half-life (palliative low dose steroids are allowed to bridge the time to CAP-100; major surgery or irradiation for CLL must have been completed > 4 weeks prior to the first trial dose of medication). Prior chimeric antigen receptor (CAR)-T cell therapy is allowed
Life expectancy > 16 weeks
Subjects must have met the diagnostic criteria for CLL according to the iwCLL 2018 guidelines (Hallek et al, 2018) or for SLL (NCCN guidelines, 2020) at some point during their disease course
Subjects must meet iwCLL 2018 guideline criteria (Hallek et al, 2018) for active disease
Platelet count 50,000/ L, unless decrease is attributable to bone marrow infiltration of CLL
Adequate liver function as indicated by aspartate transaminase (AST)/ alanine transaminase (ALT) 2.5 times upper limit of normal (ULN), unless directly attributable to the subject's tumor (in this case, acceptable levels are 5 x ULN)
Renal function as defined by creatinine clearance (CrCl) 45 mL/min (by CKD-EPI formula)
Women of childbearing potential and male subjects who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the trial and for 4 months following the completion of their last treatment. Women of childbearing potential must have a negative serum -subunit of hCG gonadotropin (-hCG) pregnancy test result within 7 days of first trial dose. Female subjects who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have -hCG pregnancy test waived

Exclusion Criteria

Allogeneic stem-cell transplantation within 6 months of trial entry
Monoclonal antibody therapy within 4 weeks of trial entry
Side effects due to prior therapy not recovered to Grade 1
Oral targeted inhibitors (Bruton's tyrosine kinase [BTK]-inhibitors, B-cell lymphoma 2 [BCL-2] inhibitors, phosphoinositide 3-kinase [PI3K] inhibitors) within five times their half-life
Active viral, bacterial or systemic fungal infection requiring treatment
Subjects who are known to be human immunodeficiency virus (HIV)-positive
Subjects with active known central nervous system (CNS) lymphoma
Pregnant or lactating women
History of previous cancer < 2 years before the trial, except controlled disease using systemic therapy with curative intent, surgical therapy with curative intent or skin cancer, cancer in situ, and prostate cancer on the "watch and wait" approach
Uncontrolled intercurrent illness including, but not limited to, New York Heart Association Class (NYHA) III and IV congestive heart failure, myocardial infraction within the previous 6 months, ejection fraction (EF) < 40%, life-threatening arrhythmias, or unstable angina brain metastasis or psychiatric illness that would limit compliance with trial requirement
Subjects with known hypersensitivity to any excipient contained in the drug formulation
Subjects with a history of documented human anti-globulin antibodies
Active autoimmune disease, motor neuropathy considered of autoimmune origin, and other CNS autoimmune disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note